What is the 13F Pro Quality Score for PFE?

13F Pro ranks PFIZER INC (PFE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PFE's current score at https://13fpro.ai/company/PFE (free sign-up required for the full ranking).

Which hedge funds own the most PFE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PFE include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/PFE as soon as new 13F filings post.

Where does 13F Pro source PFE data?

All PFIZER INC fundamentals and ownership data come directly from SEC EDGAR. PFIZER INC files with the SEC under CIK 78003. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PFE in?

PFIZER INC (PFE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives PFE's revenue?

Per PFIZER INC's latest 10-Q filed with the SEC on 2026-08-04, the biggest revenue drivers are: Primary Care ($5,503M); Eliquis ($2,425M, +21% YoY); Oncology ($4,165M). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/PFE.

What are PFE's largest expenses?

PFIZER INC's latest 10-Q reports these as the largest expense items: Cost of sales ($4,092M, +8% YoY); Other (income)/deductions—net ($3,716M); Selling, informational and administrative ($3,411M, flat YoY). Sourced directly from SEC EDGAR filing text for Q2 2026 (quarter ended June 28, 2026).

How often is PFE research updated on 13F Pro?

PFE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PFIZER INC(PFE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 78003 PFE stock profile & AI dashboard →

13F Pro Quality Score

62.0/100

Rank #735 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

48.4/100

Profitability

39.4/100

Balance Sheet

54.0/100

Earnings Quality

90.6/100

Free Cash Flow

68.9/100

Institutional Flow

59.7/100

Revenue Scale

97.5/100

Dilution Risk

50.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why PFE Scores 62/100

exact factor attribution · 2026-09-11

PFE's composite is driven by scale and earnings quality, held back by profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+7.1 pts

98th pct

Earnings quality

+4.1 pts

91th pct

Free cash flow

+2.8 pts

69th pct

Institutional flow

+0.5 pts

60th pct

Capital efficiency

+0.4 pts

54th pct

Shareholder dilution

+0.0 pts

51th pct

Revenue growth

-0.3 pts

48th pct

Earnings growth

-1.0 pts

30th pct

Profitability

-1.6 pts

39th pct

Latest change (2026-08-04): 69 → 58 · ↓ Profit margin 88→44; ↓ Capital efficiency 74→52; despite ↑ Revenue growth 31→60

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in PFE

Events flagged as statistical outliers against PFE's own multi-year baseline — not fixed dollar thresholds.

Insider cluster2026-08-12
3 insiders bought $2,960,110 of PFE in 30 days — 6.0σ above this company's 2-year norm
View source filing →
Insider cluster2026-08-05
2 insiders bought $1,959,190 of PFE in 30 days — 4.0σ above this company's 2-year norm
View source filing →
Score shock2026-08-04
PFE quality score dropped 11 points (69→58) on a new filing
View source filing →

PFE Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for PFIZER INC (PFE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PFE at 62.0/100 on a 32-signal composite quality model, placing it at rank #735 of 2,961 stocks — the top 25% of the AI-ranked universe. PFE scores in the top quartile across revenue scale (97.5), earnings quality (90.6). Areas of concern include profitability (39.4), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), PFIZER INC reports quarterly revenue of $15.0B, net income of $-248.0M, free cash flow of $302.0M. Top institutional holders of PFE by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. PFE trades on the NYSE exchange and files with the SEC under CIK 78003. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PFE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PFIZER INC directly from SEC EDGAR. PFIZER INC's 13F Pro composite quality score has ranged between 39 and 90 since 2021, currently 62.0 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about PFIZER INC

Quirks, history, and lore behind PFE — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mega-cap · listed on the NYSE · headquartered in New York City.
2
The Numbers
Annual revenue around $60 billion in a typical year, with an R&D budget that routinely tops $10 billion — because if your pill flops in Phase 3, that's a very expensive oops.
3
The History
Founded in Brooklyn in 1849 by a German-American chemist, it got its first big break supplying medicines to Union soldiers during the Civil War.
4
The Secret
It is one of the world's largest producers of penicillin and helped mass-produce it during World War II, arguably changing the outcome of the war one dose at a time.
5
The Lore
Its cholesterol drug Lipitor became the best-selling prescription drug in history, generating over $130 billion in lifetime sales — more than most countries' GDP.
6
The Giveaway
It partnered with BioNTech to deliver the world's first authorized mRNA COVID-19 vaccine in late 2020, shipping billions of doses in a race that the whole planet was watching.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving PFE's Business? Latest 10-Q Breakdown

✓ 32/32 datapoints verified

AI-extracted from PFIZER INC's 10-Q filed 2026-08-04 — Q2 2026 (quarter ended June 28, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Revenue rose 3% to $15.0B, but $4.3B of intangible asset impairments drove a $248M net loss versus $2,910M net income a year earlier.

Biggest Revenue Drivers

Primary Care$5,503M

Eliquis, Nurtec ODT/Vydura and Abrysvo growth offset by declines in Comirnaty, Paxlovid and the Prevnar family

Oncology$4,165M

Padcev up on first-line la/mUC market share and Lorbrena up on first-line ALK+ NSCLC patient share; Adcetris and Bosulif declined

Biggest Revenue Drivers

Total revenue: $15.0B+3% YoY

Primary Care$5,503M

Eliquis, Nurtec ODT/Vydura and Abrysvo growth offset by declines in Comirnaty, Paxlovid and the Prevnar family

Within Primary Care

Eliquis$2,425M+21% YoY

Higher U.S. net price from pricing dynamics including lower rebates and channel mix favorability, plus higher demand globally

Oncology$4,165M

Padcev up on first-line la/mUC market share and Lorbrena up on first-line ALK+ NSCLC patient share; Adcetris and Bosulif declined

Specialty Care$3,353M

Vyndaqel family growth from U.S. market expansion and international demand, partly offset by Xeljanz decline

Hospital and Biosimilars$1,640M

Inflectra and oncology biosimilars growth offset by declines in Sulperazon and Zithromax

Largest Expense Items

Cost of sales$4,092M+8% YoY

$130M unfavorable sales mix, $90M higher amortization of acquired inventory step-up driven by the Oxbryta impairment, $60M FX

Other (income)/deductions—net$3,716M

$4.3B intangible impairments and $842M legal charges, partly offset by a $1.870B net gain on the ViiV investment sale

Selling, informational and administrative$3,411Mflat YoY

$70M lower corporate enabling function spend offset by $40M higher cost-realignment implementation costs and $35M unfavorable FX

Research and development$2,809M+13% YoY

Anticipated $240M increase in spending on certain oncology and obesity product candidates

Margins: Cost of sales rose to 27.2% of revenues from 25.8%, driven by unfavorable sales mix and higher amortization of the fair value step-up of acquired inventory tied to the Oxbryta impairment. Management calls long-term gross margin improvement a key focus.

Watch Items from the Filing

$4.3B of impairments: $3.8B IPR&D for sigvotatug vedotin after the Phase 3 SigVie-002 study missed its overall survival endpoint, and $525M for Oxbryta.
COVID franchise collapsed: Paxlovid revenue fell 95% to $21M and Comirnaty fell 32% to $261M; excluding both, revenue grew 5% operationally.
Pfizer expects roughly $1.1 billion of unfavorable 2026 revenue impact from patent or regulatory exclusivity expiries, with the rate of decline accelerating through 2030.
New restructuring phases add ~$4.0B (manufacturing) and ~$2.0B (cost base) of one-time costs through 2029 against ~$1.5B and ~$1.0B of expected savings.
Under binding agreements with the U.S. Government, the Section 232 pharmaceutical tariff rate for Pfizer products is zero until January 20, 2029.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$15.0B

Net Income

Q2 2026

$-248.0M

Free Cash Flow

Q2 2026

$302.0M

ROIC

Q2 2026

-1.7%

D/E Ratio

Q2 2026

0.77

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-1.6% YoY

$62.58BFY 2025

FY22 $101.17BFY23 $59.55BFY24 $63.63BFY25 $62.58B

Net Income

-3.2% YoY

$7.77BFY 2025

FY22 $31.37BFY23 $2.12BFY24 $8.03BFY25 $7.77B

EPS (Diluted)

-3.5% YoY

$1.36FY 2025

FY22 $5.47FY23 $0.37FY24 $1.41FY25 $1.36

Total Assets

-2.5% YoY

$208.16BFY 2025

FY22 $197.21BFY23 $226.50BFY24 $213.40BFY25 $208.16B

Total Debt

-0.4% YoY

$67.79BFY 2025

FY22 $38.39BFY23 $74.14BFY24 $68.10BFY25 $67.79B

Op. Cash Flow

-8.2% YoY

$11.70BFY 2025

FY22 $29.27BFY23 $8.70BFY24 $12.74BFY25 $11.70B

Free Cash Flow

-7.7% YoY

$9.07BFY 2025

FY22 $26.03BFY23 $4.79BFY24 $9.84BFY25 $9.07B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$62.58B -1.6%	$63.63B +6.8%	$59.55B -41.1%	$101.17B +24.5%	$81.29B +95.2%	$41.65B
Net Income	$7.77B -3.2%	$8.03B +279.0%	$2.12B -93.2%	$31.37B +42.7%	$21.98B +140.0%	$9.16B
EPS (Diluted)	$1.36 -3.5%	$1.41 +281.1%	$0.37 -93.2%	$5.47 +42.1%	$3.85 +136.2%	$1.63
Total Assets	$208.16B -2.5%	$213.40B -5.8%	$226.50B +14.9%	$197.21B +8.7%	$181.48B +17.7%	$154.23B
Total Debt	$67.79B -0.4%	$68.10B -8.2%	$74.14B +93.1%	$38.39B -4.2%	$40.07B -4.2%	$41.84B
Operating Cash Flow	$11.70B -8.2%	$12.74B +46.5%	$8.70B -70.3%	$29.27B -10.2%	$32.58B +126.2%	$14.40B
Free Cash Flow	$9.07B -7.7%	$9.84B +105.2%	$4.79B -81.6%	$26.03B -12.8%	$29.87B +145.3%	$12.18B

Get alerted when PFE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PFIZER INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PFE

BlackRock, Inc.
$12.8B529,670,433 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.0B372,149,852 sh
STATE STREET CORP
$7.4B307,090,897 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.2B135,275,782 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.9B119,235,030 sh
Fisher Asset Management, LLC
$2.6B109,067,291 sh
MORGAN STANLEY
$2.3B96,345,452 sh
NORGES BANK
$1.5B61,505,586 sh
NORTHERN TRUST CORP
$1.4B59,084,573 sh
Bank of New York Mellon Corp
$1.4B57,879,546 sh

Fund	Value	Shares
BlackRock, Inc.	$12.8B	529,670,433
VANGUARD CAPITAL MANAGEMENT LLC	$9.0B	372,149,852
STATE STREET CORP	$7.4B	307,090,897
GEODE CAPITAL MANAGEMENT, LLC	$3.2B	135,275,782
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.9B	119,235,030
Fisher Asset Management, LLC	$2.6B	109,067,291
MORGAN STANLEY	$2.3B	96,345,452
NORGES BANK	$1.5B	61,505,586
NORTHERN TRUST CORP	$1.4B	59,084,573
Bank of New York Mellon Corp	$1.4B	57,879,546

Companies Similar to PFE

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

MRK

Merck & Co., Inc.

AI score

Highly similar · 41 shared holders

STATE FARM MUTUAL AUTOMOBILE INSURANCE CO PeakShares LLC LSV ASSET MANAGEMENT

ABT

ABBOTT LABORATORIES

AI score

Very similar · 30 shared holders

STATE FARM MUTUAL AUTOMOBILE INSURANCE CO National Pension Service PeakShares LLC

BMY

BRISTOL MYERS SQUIBB CO

AI score

Very similar · 53 shared holders

LSV ASSET MANAGEMENT National Pension Service Robeco Institutional Asset Management B.V.

ABBV

AbbVie Inc.

AI score

Very similar · 45 shared holders

STATE FARM MUTUAL AUTOMOBILE INSURANCE CO Capital World Investors National Pension Service

CVS

CVS HEALTH Corp

AI score

Very similar · 42 shared holders

Capital World Investors LSV ASSET MANAGEMENT National Pension Service

UNH

UNITEDHEALTH GROUP INC

AI score

Very similar · 30 shared holders

Capital World Investors National Pension Service PeakShares LLC

MDT

Medtronic plc

AI score

Very similar · 42 shared holders

Capital World Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO National Pension Service

JNJ

JOHNSON & JOHNSON

AI score

Very similar · 39 shared holders

STATE FARM MUTUAL AUTOMOBILE INSURANCE CO Capital World Investors PeakShares LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PFE on your watchlist

Track score changes the day PFIZER INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PFE a good stock to buy?

13F Pro's AI-powered analysis of PFIZER INC (PFE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PFE are available on the PFE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PFE is classified as a large company.

Which hedge funds own PFE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PFE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PFIZER INC's investment landscape.